Register to make submissions to the MHRA

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) issued guidance for pharmaceutical companies, clinical trial sponsors, and medical brokers regarding the mandatory use of national portals for UK and Great Britain (GB) marketing authorizations and vigilance activities. This framework facilitates the transition from European Union (EU) procedures to direct UK reporting following regulatory changes. Unlike an inspection report, this document focuses on procedural compliance rather than specific violations or company-specific enforcement actions. It outlines the requirements for organizations to gain access to 'MHRA Submissions,' the primary portal for managing regulatory data, clinical trial notifications, and safety reports. Required actions for stakeholders include: 1. Identifying their unique five-digit MHRA company number. 2. Appointing an initial company administrator to manage user permissions. 3. Registering for the MHRA Gateway or the ICSR Submissions portal for transmitting Individual Case Safety Reports (ICSRs) and Suspected Unexpected Serious Adverse Reactions (SUSARs). 4. Ensuring all new safety cases are submitted directly to the UK system instead of the European Medicines Agency (EMA). The MHRA emphasizes that while EU portals like CESP remain relevant for European procedures, the UK-specific portals are necessary for all domestic licenses. Organizations are encouraged to review provided video tutorials and user guides to ensure administrative setup is completed correctly, as this is essential for generating product licensing numbers and maintaining regulatory compliance within the UK market.